JP6077541B2 - ワクチンのための分子アジュバントとしてのｐａｃａｐの使用 - Google Patents

ワクチンのための分子アジュバントとしてのｐａｃａｐの使用 Download PDF

Info

Publication number
JP6077541B2
JP6077541B2 JP2014526385A JP2014526385A JP6077541B2 JP 6077541 B2 JP6077541 B2 JP 6077541B2 JP 2014526385 A JP2014526385 A JP 2014526385A JP 2014526385 A JP2014526385 A JP 2014526385A JP 6077541 B2 JP6077541 B2 JP 6077541B2
Authority
JP
Japan
Prior art keywords
pacap
group
fish
peptide
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014526385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524450A (ja
JP2014524450A5 (enExample
Inventor
ゴンザレス、フアナ、マリア ルーゴ
ゴンザレス、フアナ、マリア ルーゴ
ゴンザレス、ヤミーラ カプリオ
ゴンザレス、ヤミーラ カプリオ
ガルシア、マリオ、パブロ エストラーダ
ガルシア、マリオ、パブロ エストラーダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of JP2014524450A publication Critical patent/JP2014524450A/ja
Publication of JP2014524450A5 publication Critical patent/JP2014524450A5/ja
Application granted granted Critical
Publication of JP6077541B2 publication Critical patent/JP6077541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014526385A 2011-08-26 2012-08-24 ワクチンのための分子アジュバントとしてのｐａｃａｐの使用 Active JP6077541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
CU2011-0167 2011-08-26
PCT/CU2012/000004 WO2013029570A1 (es) 2011-08-26 2012-08-24 Uso del pacap como adyuvante molecular para vacunas

Publications (3)

Publication Number Publication Date
JP2014524450A JP2014524450A (ja) 2014-09-22
JP2014524450A5 JP2014524450A5 (enExample) 2015-04-02
JP6077541B2 true JP6077541B2 (ja) 2017-02-08

Family

ID=47046313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526385A Active JP6077541B2 (ja) 2011-08-26 2012-08-24 ワクチンのための分子アジュバントとしてのｐａｃａｐの使用

Country Status (20)

Country Link
US (1) US9549977B2 (enExample)
EP (1) EP2749291B1 (enExample)
JP (1) JP6077541B2 (enExample)
KR (1) KR101857705B1 (enExample)
CN (1) CN103874510A (enExample)
AU (1) AU2012303887B2 (enExample)
BR (1) BR112014004620B1 (enExample)
CA (1) CA2844898C (enExample)
CL (1) CL2014000386A1 (enExample)
CU (1) CU24075B1 (enExample)
ES (1) ES2648337T3 (enExample)
MX (1) MX351725B (enExample)
MY (1) MY191697A (enExample)
NO (1) NO2749291T3 (enExample)
PH (1) PH12014500397B1 (enExample)
PT (1) PT2749291T (enExample)
RU (1) RU2580294C2 (enExample)
SG (1) SG11201400215SA (enExample)
WO (1) WO2013029570A1 (enExample)
ZA (1) ZA201401271B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060057A (ko) 2017-11-24 2019-06-03 유병희 웰빙 무드등
EP3970796B1 (en) * 2019-05-14 2025-08-20 Senju Pharmaceutical Co., Ltd. Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide
CN117617183B (zh) * 2023-11-29 2025-09-05 中国医学科学院医药生物技术研究所 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65568B1 (en) * 1990-10-22 1995-11-01 Unilever Plc Vaccine compositions for fish
PE20010612A1 (es) * 1999-09-28 2001-07-12 Bayer Corp Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
CU23557A1 (es) 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos
CN102883739B (zh) * 2009-11-02 2015-11-25 图兰恩教育基金管理人 垂体腺苷酸环化酶激活多肽（pacap）的类似物和它们的应用方法
CN103255089B (zh) * 2013-05-03 2015-08-05 中国水产科学研究院黄海水产研究所 一株强毒迟缓爱德华氏菌疫苗株及其应用

Also Published As

Publication number Publication date
AU2012303887B2 (en) 2017-06-22
PH12014500397B1 (en) 2018-09-12
KR20140064847A (ko) 2014-05-28
JP2014524450A (ja) 2014-09-22
PT2749291T (pt) 2017-11-24
CA2844898A1 (en) 2013-03-07
BR112014004620A2 (pt) 2017-03-21
CU24075B1 (es) 2015-01-29
EP2749291A1 (en) 2014-07-02
RU2014111465A (ru) 2015-10-10
MY191697A (en) 2022-07-07
CA2844898C (en) 2021-06-22
MX351725B (es) 2017-10-25
CU20110167A7 (es) 2013-06-28
ZA201401271B (en) 2015-04-29
US9549977B2 (en) 2017-01-24
US20140294889A1 (en) 2014-10-02
MX2014002214A (es) 2014-04-30
AU2012303887A1 (en) 2014-03-06
ES2648337T3 (es) 2018-01-02
RU2580294C2 (ru) 2016-04-10
BR112014004620B1 (pt) 2019-10-29
PH12014500397A1 (en) 2014-04-14
NO2749291T3 (enExample) 2018-03-17
KR101857705B1 (ko) 2018-06-20
CL2014000386A1 (es) 2014-07-11
CN103874510A (zh) 2014-06-18
EP2749291B1 (en) 2017-10-18
SG11201400215SA (en) 2014-09-26
WO2013029570A1 (es) 2013-03-07

Similar Documents

Publication Publication Date Title
Chang et al. Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model
Ballesteros et al. An oral DNA vaccine against infectious haematopoietic necrosis virus (IHNV) encapsulated in alginate microspheres induces dose-dependent immune responses and significant protection in rainbow trout (Oncorrhynchus mykiss)
Chang et al. Protection of Atlantic salmon against virus infection by intramuscular injection of IFNc expression plasmid
Chen et al. Molecular characterization and expression analysis of the IFN-gamma related gene (IFN-γrel) in grass carp Ctenopharyngodon idella
Thwaite et al. Nanostructured recombinant protein particles raise specific antibodies against the nodavirus NNV coat protein in sole
Leal et al. Functional nutrition modulates the early immune response against viral haemorrhagic septicaemia virus (VHSV) in rainbow trout
Santos et al. Influence of pigeon interferon alpha (PiIFN-α) on pigeon circovirus (PiCV) replication and cytokine expression in Columba livia
JP6077541B2 (ja) ワクチンのための分子アジュバントとしてのｐａｃａｐの使用
Parhi et al. Molecular characterization and expression analysis of interferon γ (IFN-γ) gene in Labeo rohita (Ham.)
Gorgoglione et al. Viral and bacterial septicaemic infections modulate the expression of PACAP splicing variants and VIP/PACAP receptors in brown trout immune organs
EP2950816B1 (en) The use of dna sequences encoding an interferon as vaccine adjuvants
Sepúlveda et al. Time-course study of the protection induced by an interferon-inducible DNA vaccine against viral haemorrhagic septicaemia in rainbow trout
Jittimanee et al. Protective immunization of hamsters against Opisthorchis viverrini infection is associated with the reduction of TGF-β expression
Martinez-Alonso et al. Immune responses elicited in rainbow trout through the administration of infectious pancreatic necrosis virus-like particles
EP4382533A1 (en) Protein nanopellets for fish or teleost and crustacean vaccination
Sivasankar et al. Analysis of immune gene expression in seabass (Lates calcarifer) immunized with inactivated vaccine against similar damselfish virus
Martín-Martín et al. Potential of the Escherichia coli LT (R192G/L211A) toxoid as a mucosal adjuvant for rainbow trout (Oncorhynchus mykiss)
JP5997702B2 (ja) 水生生物におけるウイルス感染を処置するためのｐａｃａｐの使用
JP5971625B2 (ja) アジュバント、及び水産用ワクチン
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
Carrera et al. Evaluating the adjuvant potential of NK-lysin and HMGB1-derived peptides in enhancing immune responses in Salmo salar
Leiva-Rebollo et al. Evaluation of Gilthead Seabream (Sparus aurata) Immune Response after LCDV-Sa DNA Vaccination. Animals 2021, 11, 1613
Kaviarasu et al. Bacterial DNA pre-stimulation elevates antiviral gene expression in koi against koi ranavirus (KIRV) infection
EP3037539A1 (en) Recombinant vaccine against viral hemorrhagic septicemia virus
Chaves-Pozo et al. Antiviral DNA vaccination in rainbow trout (Oncorhynchus mykiss) affects the immune response in the ovary and partially blocks its capacity to support viral replication in vitro

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170112

R150 Certificate of patent or registration of utility model

Ref document number: 6077541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250